Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05048264 · ClinicalTrials.gov registry record
Effect of Corticosteroid Injections on Blood Glucose
A clinical trial, sponsored by Duke University.
- Terminated
- Registry status
- 38
- Enrollment target
NCT05048264: Clinical Trial study, sponsored by Duke University.
NCT05048264 is a clinical trial that was terminated before completion, run by Duke University. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05048264 was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effect of various corticosteroids administered to the shoulder, knee and hip joints in diabetic patients on resultant blood glucose readings.
Primary Outcome
Reported daily glucose measures from baseline to two week after injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2024-09-16 |
Why NCT05048264 stopped before completion
NCT05048264 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05048264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05048264 about?
NCT05048264 is a clinical study titled "Effect of Corticosteroid Injections on Blood Glucose". The purpose of this study is to measure the effect of various corticosteroids administered to the shoulder, knee and hip joints in diabetic patients on resultant blood glucose readings.
What is the current status of trial NCT05048264?
This trial is currently terminated. The enrollment target is 38 participants. The study started on 2023-05-04. Estimated completion is 2024-09-16.
Who is sponsoring clinical trial NCT05048264?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI